R N Jones

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. ncbi request reprint Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:71-4. 2005
  2. pmc Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan
    Wen Liang Yu
    China Medical College Hospital, Taichung, Taiwan
    Emerg Infect Dis 8:522-4. 2002
  3. doi request reprint Resistance surveillance program report for selected European nations (2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa, USA Electronic address
    Diagn Microbiol Infect Dis 78:429-36. 2014
  4. ncbi request reprint Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa, USA Electronic address
    Braz J Infect Dis 17:672-81. 2013
  5. doi request reprint Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 76:237-8. 2013
  6. doi request reprint Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 76:239-40. 2013
  7. doi request reprint More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 76:110-2. 2013
  8. doi request reprint Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:357-60. 2013
  9. doi request reprint Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:402-5. 2013
  10. doi request reprint Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:304-7. 2013

Collaborators

Detail Information

Publications205 found, 100 shown here

  1. ncbi request reprint Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:71-4. 2005
    ..016 mug/mL (with higher values for ertapenem). Doripenem appears to be a promising, potent carbapenem for parenteral use against contemporary Gram-negative bacilli producing various beta-lactamases...
  2. pmc Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan
    Wen Liang Yu
    China Medical College Hospital, Taichung, Taiwan
    Emerg Infect Dis 8:522-4. 2002
    ..Continued use of cefepime appears to be a treatment option in cases for which MIC results are available and interpreted by the criteria presented...
  3. doi request reprint Resistance surveillance program report for selected European nations (2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa, USA Electronic address
    Diagn Microbiol Infect Dis 78:429-36. 2014
    ....
  4. ncbi request reprint Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa, USA Electronic address
    Braz J Infect Dis 17:672-81. 2013
    ....
  5. doi request reprint Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 76:237-8. 2013
    ..Generic antimicrobial products, in general, should be regularly monitored for potency, chemical purity, and in vivo activity before routine use in medical centers...
  6. doi request reprint Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 76:239-40. 2013
    ..8% of tested strains were inhibited at dalbavancin MIC values at ≤0.12 μg/mL. Dalbavancin remains very potent against rarer Gram-positive pathogens, using in vitro test experience with organisms cultured through 2011...
  7. doi request reprint More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 76:110-2. 2013
    ....
  8. doi request reprint Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:357-60. 2013
    ....
  9. doi request reprint Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:402-5. 2013
    ..5 or ≤1 μg/mL) represent the most conservative (better recognize strains with tet resistance mechanisms) and accurate tetracycline breakpoint guidelines for testing contemporary isolates of Gram-positive cocci...
  10. doi request reprint Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:304-7. 2013
    ..In conclusion, year 2011 SENTRY Program data for DAL documents sustained potent activity against SA, CoNS, βHS, VGS, and VAN-S enterococci, which averaged 4- to 32-fold greater than VAN, DAP, or linezolid...
  11. doi request reprint Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 75:107-9. 2013
    ..0%). In summary, resistance rates to several antimicrobials continue to rise after introductions of both pneumococcal conjugate vaccines, as noted from these results for 1998 through 2011...
  12. doi request reprint Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 75:89-93. 2013
    ..11%). These presented analyses offer a validated surrogate marker strategy for ceftaroline susceptibility testing, pending development and validation by the commonly used automated systems and agar diffusion commercial methods...
  13. pmc Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    BMC Infect Dis 7:29. 2007
    ..We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005...
  14. ncbi request reprint Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Clin Infect Dis 42:S13-24. 2006
    ....
  15. ncbi request reprint Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
    Ronald N Jones
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 57:279-87. 2006
    ..To investigate the activity of linezolid (an oxazolidinone), a potent choice for community- and hospital-acquired infections, via a worldwide surveillance network called the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program...
  16. ncbi request reprint A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India
    Ronald N Jones
    JMI Laboratories The Jones Group, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 20:426-31. 2002
    ..high levels of co-resistance between the tested beta-lactam agents and ciprofloxacin and the aminoglycosides, gentamicin and tobramycin. However, carbapenems such as meropenem, remain a therapeutic option...
  17. ncbi request reprint Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 44:93-100. 2002
    ..These results support recommendations to treat CAP, particularly due to S. pneumoniae including multidrug-resistant strains, with the newer 8-methoxy-fluoroquinolone, gatifloxacin...
  18. ncbi request reprint In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 50:915-32. 2002
    ....
  19. ncbi request reprint An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:247-56. 2005
    ..Thus, antipseudomonal carbapenems such as meropenem and imipenem remain an effective treatment option...
  20. ncbi request reprint Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 43:239-43. 2002
    ..In all regions, aminoglycosides in combination with carbapenems, cefepime, or piperacillin/tazobactam would provide more potential antipseudomonal activity than fluoroquinolone combinations for wide-spectrum empiric regimens...
  21. ncbi request reprint Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:63-71. 2006
    ..TAO maintains a wider spectrum of activity compared with mupirocin and was usable against mupirocin-resistant Gram-positive strains...
  22. ncbi request reprint Determining the value of antimicrobial surveillance programs
    R N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 41:171-5. 2001
    ..The MYSTIC Program and other assessed networks appear to be both valuable and complementary in their design and function...
  23. pmc Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    J Clin Microbiol 40:461-5. 2002
    ....
  24. pmc Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 47:2696-8. 2003
    ..Similar gene duplication has been reported in Q/D-resistant Staphylococcus aureus...
  25. ncbi request reprint Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 42:137-9. 2002
    ....
  26. ncbi request reprint Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?
    Ronald N Jones
    The JONES Group and JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 42:213-5. 2002
    ..Local susceptibility testing data must be assessed before fluoroquinolone empiric therapy can be used with confidence...
  27. ncbi request reprint Fluoroquinolones for the treatment of outpatient community-acquired pneumonia
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 44:69-76. 2002
    ..This overview of the fluoroquinolones directs particular attention to use in community-acquired pneumonia and safety...
  28. ncbi request reprint Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:149-53. 2006
    ..Dalbavancin wild-type MIC distributions remain unchanged compared with prior sampled years (2002-2003) in the USA...
  29. ncbi request reprint AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains
    R N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 43:87-90. 2002
    ..AZD2563 remained active (MIC, < or = 1 microg/ml) against all 10 strains tested...
  30. ncbi request reprint Microbiology of newer fluoroquinolones: focus on respiratory pathogens
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 44:213-20. 2002
    ..The mechanisms and prevalence of resistance of beta-lactam antimicrobials, macrolides, and fluoroquinolones also are reviewed...
  31. ncbi request reprint Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:235-46. 2005
    ....
  32. ncbi request reprint Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone
    R N Jones
    JMI Laboratories The Jones Group, 345 Beaver Kreek Center, Suite A, North Liberty, Iowa 52317, USA
    Clin Microbiol Infect 9:543-6. 2003
    ....
  33. ncbi request reprint Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe
    R N Jones
    Tufts University School of Medicine, Jones Group JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, Iowa 52317, USA
    Clin Microbiol Infect 9:708-12. 2003
    ..International surveillance initiatives should be maintained to monitor future progression of this important resistance...
  34. ncbi request reprint Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997-2001)
    Jennifer M Stephen
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 22:395-405. 2003
    ..BSIs for the commonly used antimicrobial classes. With the exception of S. Typhimurium DT104, most Salmonella spp. remain highly susceptible to the tested antimicrobials that maybe utilized for Salmonella BSI...
  35. pmc Activities of doripenem (S-4661) against drug-resistant clinical pathogens
    Ronald N Jones
    The JONES Group JMI Laboratories, Inc, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 48:3136-40. 2004
    ....
  36. ncbi request reprint Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 49:211-6. 2004
    ..09% of all PSA isolates). Meropenem remained the most active antimicrobial agent tested in the program, and surveillance networks must implement epidemiologic typing to accurately assess the role of clonal spread on the study results...
  37. ncbi request reprint Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 54:144-54. 2004
    ..To investigate the potency of doripenem, a broad-spectrum carbapenem characterized by a wider spectrum of activity combining antimicrobial and bactericidal features of imipenem and meropenem...
  38. ncbi request reprint Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:147-9. 2004
    ....
  39. ncbi request reprint Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 53:804-7. 2004
    ..To evaluate the potency of a novel peptide deformylase inhibitor, NVP PDF-713, against Gram-positive organisms having resistances to linezolid or quinupristin/dalfopristin...
  40. ncbi request reprint Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 46:77-80. 2003
    ..Continued local and global surveillance of resistances in common respiratory tract pathogens such as S. pneumoniae appears to be prudent practice to guide effective chemotherapy...
  41. ncbi request reprint Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:289-94. 2004
    ....
  42. ncbi request reprint Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:129-33. 2005
    ..Parenteral cephalosporins (cefepime or ceftriaxone) continue to be potent and safe for use in hospitalized patients with S. pneumoniae community-acquired pneumonia, used with or without co-drugs according to published guidelines...
  43. ncbi request reprint Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 23:197-9. 2004
    ..9-92.2% of dalbavancin MIC comparisons. These dalbavancin MIC results demonstrated the acceptable accuracy of commercially-prepared broth microdilution products for use in subsequent clinical trials...
  44. ncbi request reprint Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000)
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 21:1-7. 2003
    ..Co-resistance to other antimicrobial agents was common in both tested genus groups...
  45. ncbi request reprint Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis)
    Ronald N Jones
    The JONES Group, JMI Laboratories Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 51:139-41. 2005
    ..meningitidis and N. gonorrhoeae, respectively. All comparison agents were more active than this peptide deformylase inhibitor against this genus...
  46. ncbi request reprint Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 44:379-82. 2002
    ..This study confirms the need for constant monitoring of in vitro antimicrobial efficacy to direct empiric treatment regimens...
  47. pmc Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods
    Ronald N Jones
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 43:925-7. 2005
    ..25 to 2 microg/ml (11 to 17 mm), and for polymyxin B, 0.25 to 2 mug/ml (14 to 18 mm). More than 97% of all reported QC results were within these proposed ranges...
  48. ncbi request reprint Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections
    Thomas R Fritsche
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 24:567-71. 2004
    ....
  49. ncbi request reprint Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study
    R N Jones
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 53:258-65. 2004
    ..This study uses a new des-F(6)quinolone, garenoxacin, to compare in vitro results among the most utilized antimicrobial susceptibility testing methods...
  50. ncbi request reprint Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:109-16. 2007
    ..4% and 2.3%, respectively). Our results indicate that cefepime was the most broad-spectrum cephalosporin analyzed and remains a very potent alternative for the treatment of contemporary pediatric infections in North America...
  51. pmc Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 51:1491-3. 2007
    ..25 to 2 microg/ml; MIC90 range, 0.25 to 2 microg/ml). Only one isolate (viridans group streptococcus; 0.03% of tested strains) was resistant to linezolid...
  52. doi request reprint In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 512317, USA
    Diagn Microbiol Infect Dis 63:339-41. 2009
    ..Lack of cross-resistances for iclaprim with other commonly used therapies could make iclaprim an alternative for several sexually transmitted diseases (gonococci, Chlamydia trachomatis)...
  53. pmc Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 44:2622-5. 2006
    ..Vancomycin test results most reliably predict dalbavancin susceptibility until validated commercial reagents become available for direct testing in clinical practice...
  54. ncbi request reprint Development of anidulafungin for disk diffusion susceptibility testing against Candida spp
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:371-4. 2007
    ....
  55. ncbi request reprint Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:9-17. 2007
    ....
  56. pmc Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 51:3381-4. 2007
    ..Clinical results remained identical (89% cures) regardless of the antimicrobial used or CO-MRSA molecular patterns, PVL production, or antimicrobial susceptibility profiles...
  57. ncbi request reprint LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 59:309-17. 2007
    ..Overall, 99.55% of the tested 2006 LEADER program isolates remained susceptible to linezolid at current Clinical and Laboratory Standards Institute breakpoints...
  58. ncbi request reprint Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 59:467-72. 2007
    ....
  59. doi request reprint In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:76-9. 2008
    ..The average -16% activity across all generic lots was equivalent to underdosing piperacillin/tazobactam by 2.6 g daily for serious clinical infections (4.5 g Q6 h)...
  60. doi request reprint Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:203-13. 2008
    ....
  61. pmc Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    J Clin Microbiol 45:227-30. 2007
    ..led to an unacceptable error rate (23.3%). However, an adjustment of tigecycline disk diffusion breakpoints (susceptible/resistant) to > or =16/ < or =12 mm reduced intermethod errors to an acceptable level (only 9.7%, all minor)...
  62. doi request reprint ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 64:191-201. 2009
    ..Clonal outbreaks with patient-to-patient dissemination were documented in 1 Italian site. Linezolid appears to retain excellent activity against monitored Gram-positive pathogens at a level of >99.8%...
  63. doi request reprint Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:404-13. 2009
    ..Rates of clindamycin resistance and the frequency of MRSA varied by geographic region and between nations; therefore, like oxazolidinones, it requires continued surveillance for changing resistance patterns...
  64. doi request reprint United States resistance surveillance results for linezolid (LEADER Program for 2007)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA Tufts University School of Medicine, Boston, MA 02111, USA
    Diagn Microbiol Infect Dis 62:416-26. 2008
    ..aureus and Staphylococcus epidermidis strains from Arizona and Ohio. The LEADER Program appears to be an effective and sensitive surveillance tool to detect novel resistance phenotypes and genotypes...
  65. doi request reprint In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa, USA
    Clin Infect Dis 52:S477-86. 2011
    ..Fusidic acid is a promising oral therapy for staphylococcal skin and skin structure infections in the United States, where the contemporary S. aureus population remains without significant resistance...
  66. ncbi request reprint Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 55:351-6. 2006
    ..Cefdinir should be considered as a viable option for the therapy uSSTI caused by indicated species...
  67. ncbi request reprint In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains
    R N Jones
    University of Iowa College of Medicine, Iowa City, USA
    J Chemother 13:363-76. 2001
    ..These results from testing 902 organisms indicate that ertapenem appears to be a promising broad-spectrum carbapenem with a possible role against some emerging resistant species...
  68. doi request reprint Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity
    Donald Biek
    Cerexa, Inc, Oakland, CA 94612, USA
    J Antimicrob Chemother 65:iv9-16. 2010
    ..8% of all baseline cSSSI isolates from the microbiologically evaluable population were inhibited by ceftaroline at ≤ 2 mg/L. Ceftaroline fosamil is a promising broad-spectrum agent for the treatment of cSSSIs...
  69. doi request reprint Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 66:iii69-80. 2011
    ....
  70. doi request reprint Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 65:iv17-31. 2010
    ..To assess the spectrum and potency of ceftaroline, a novel anti-methicillin-resistant staphylococcal cephalosporin, against a 2008 surveillance collection of clinical isolates from patients in the USA and Europe...
  71. doi request reprint Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 51:S81-7. 2010
    ..These facts have profound impact on the choices of comparison therapies to be applied in contemporary new drug clinical trials for pneumonia...
  72. doi request reprint Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Ste A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 36:197-204. 2010
    ..This article reviews information on antimicrobial resistance patterns amongst S. pneumoniae and implications for managing CAP...
  73. pmc MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Clin Microbiol 48:1470-3. 2010
    ..The 15-microg CEM-101 disk was selected, and MIC ranges for a total of four QC organisms were proposed, with only three doubling dilutions each that included 95.6 to 99.7% of values reported from the eight-laboratory investigation...
  74. doi request reprint Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 62:110-2. 2008
    ..This novel naphthyridine should be explored as an alternative therapy for quinolone-nonsusceptible gonorrhea and Chlamydia trachomatis infections...
  75. ncbi request reprint Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Gary J Moet
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:7-13. 2007
    ..48.0%) when compared with other regions. Continued surveillance of pathogen prevalence and antimicrobial resistance patterns should provide information that is important to improve empiric care particularly in the hospital environment...
  76. ncbi request reprint Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
    Jennifer M Streit
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:307-10. 2005
    ..In summary, dalbavancin was very active against a wide spectrum of resistant Gram-positive isolates and demonstrated greater potency than vancomycin or teicoplanin...
  77. ncbi request reprint Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000)
    Jeffrey T Kirby
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 43:303-9. 2002
    ..pneumoniae) was documented in all three monitored regions (Latin America > Europe > North America). Continued development of garenoxacin as a treatment of pathogens that commonly cause SSTIs appears to be warranted...
  78. pmc CEM-101 activity against Gram-positive organisms
    Leah N Woosley
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:2182-7. 2010
    ....
  79. ncbi request reprint Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Stud
    A C Gales
    Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Int J Infect Dis 4:75-84. 2000
    ..The dissemination of multidrug-resistant methicillin-resistant Staphylococcus aureus (MDR-MRSA) among the Latin American countries also was studied...
  80. ncbi request reprint Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
    R N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 41:161-3. 2001
    ..aeruginosa clinical isolates...
  81. ncbi request reprint Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003)
    David M Johnson
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 56:69-74. 2006
    ....
  82. ncbi request reprint Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections
    David M Johnson
    JMI Laboratories The Jones Group, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 43:49-60. 2002
    ....
  83. ncbi request reprint Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program
    Lalitagauri M Deshpande
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:231-6. 2004
    ....
  84. ncbi request reprint Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America
    Paul R Rhomberg
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:365-72. 2003
    ..Carbapenem resistance remains rarely documented and these beta-lactamase-stable agents appear to be an alternative treatment option for serious community-acquired or nosocomial infections in high risk patient populations...
  85. ncbi request reprint Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 56:367-72. 2006
    ..The escalating occurrence (0.35%) of serine carbapenemases could compromise the role of carbapenems and other beta-lactams in USA clinical practice although observed in only a few locations to date...
  86. ncbi request reprint BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000)
    Kelley A Gordon
    University of Iowa College of Medicine, Iowa City, USA
    J Antimicrob Chemother 49:851-5. 2002
    ..03-1 mg/L). With a proposed breakpoint of < or =4 mg/L, BMS284756 may be a therapeutic alternative pending the results of clinical trials...
  87. pmc First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:2244-6. 2008
    ..We describe the first detection of cfr-mediated linezolid resistance in Staphylococcus aureus and Staphylococcus epidermidis recovered from human infection cases monitored during the 2007 LEADER Program...
  88. ncbi request reprint Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002)
    Douglas J Biedenbach
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 50:59-69. 2004
    ..Surveillance of BSI pathogens is needed to determine trends of resistance and provide useful information regarding patient risk factors and geographic differences...
  89. doi request reprint Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada
    Michael A Pfaller
    University of Iowa College of Medicine, Iowa City, IA, USA
    Int J Antimicrob Agents 35:282-7. 2010
    ..Fusidic acid was equally active against community-acquired MRSA and linezolid-resistant staphylococci. Fusidic acid exhibited equal or greater potency against staphylococci compared with vancomycin, daptomycin and linezolid...
  90. ncbi request reprint Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Ant
    Jennifer M Streit
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 27:367-75. 2006
    ....
  91. pmc International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003)
    Shawn A Messer
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 44:1782-7. 2006
    ....
  92. doi request reprint Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 63:440-6. 2009
    ....
  93. ncbi request reprint Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005)
    Michael A Pfaller
    University of Iowa, Iowa City, IA 52242, USA
    Diagn Microbiol Infect Dis 57:459-65. 2007
    ..5, and 1 microg/mL for staphylococci, enterococci, beta-hemolytic streptococci, and viridans group streptococci, respectively, and no significant loss in potency was observed over the period studied...
  94. ncbi request reprint In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains
    C M Flynn
    Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA
    J Chemother 8:411-5. 1996
    ..Levofloxacin activity against P. aeruginosa was most comparable to that of ciprofloxacin, which was applicable against > 90% of strains found to be resistant to other classes of antimicrobial agents...
  95. ncbi request reprint Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains
    D J Biedenbach
    The JONES Group/JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 41:225-8. 2001
    ..002-0.008 microg/mL), S. pneumoniae ATCC (26-33 mm/0.016-0.06 microg/mL). The proportion of participant results observed within the proposed ranges was 97.4-98.8% and 94.6-100% for the disk diffusion and MIC tests, respectively...
  96. ncbi request reprint Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America)
    D Mathai
    University of Iowa College of Medicine, Iowa City, IA, USA
    Diagn Microbiol Infect Dis 40:129-36. 2001
    ....
  97. ncbi request reprint Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program
    D M Johnson
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:373-6. 2003
    ..It is apparent from this investigation that many commonly prescribed empiric treatments remain viable therapeutic options for CARTI caused by these two Gram-negative respiratory tract pathogens...
  98. ncbi request reprint Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
    Jennifer M Streit
    The JONES Group JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IW 52317, USA
    Int J Antimicrob Agents 24:111-8. 2004
    ..Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America...
  99. ncbi request reprint Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:547-50. 2003
    ....
  100. ncbi request reprint Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme
    Mark A Toleman
    Department of Pathology and Microbiology, University of Bristol, Bristol, UK The JONES Group JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 55:61-70. 2005
    ....
  101. ncbi request reprint Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections
    Michael A Pfaller
    CAST Laboratories, University of Iowa College of Medicine, Iowa City, Iowa, USA
    Diagn Microbiol Infect Dis 44:77-84. 2002
    ..catarrhalis in CARTI, and high fluoroquinolone potency/spectrum (>97% susceptible). beta-lactams and macrolides continue to be compromised by increasing resistances in pathogens isolated in these monitored primary care settings...